Canton Strategic Holdings completed the sale of Gravitas Life Sciences to Gravitas Collective Corp, a transaction approved by an independent special committee and closed in mid-July 2026, with terms including a promissory note and milestone economics while retaining certain assets. The move represents a strategic shift away from owning the biotech unit toward monetizing the deal through finance and milestones and focusing on Canton’s core digital-asset and blockchain initiatives. The company’s board unanimously endorsed the sale, reinforcing governance safeguards around related-party transactions and the conversion of Gravitas into Gravitas LLC during the process. Insiders’ activity in the period shows modest selling with no reported purchases, suggesting limited internal capital shifts related to the divestiture. Coverage highlights Canton Strategic’s pivot to the Canton Network and Canton Coin, aiming to bolster its digital-asset treasury and institutional blockchain adoption, with GV104 remaining a key clinical asset target. Market context notes volatility and mixed valuation signals as the company refocuses its business model around technology and digital finance platforms.